>
>
MONTREAL, Aug. 02, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and
New sub-analysis on Trogarzo clinical trial patients demonstrates that long-term viral suppression is not influenced by partially active agents. Predictive pharmacokinetic modelling shows that new
MONTREAL, July 27, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization
The stock price of Theratechnologies Inc (NASDAQ: THTX) increased by 6.34% in the previous trading session. This is why. The stock price of Theratechnologies Inc
– Q2 2022 Consolidated Sales Growth of 8.3% to $19.3 million – Year-to-Date Revenue Growth of 13.9% or $37.8 million – Year-to-Date EGRIFTA SV® Revenue
Confirmed safety profile at 300 mg/m2 or 1.5 times the therapeutic dose of docetaxel alone Confirmed low levels of free docetaxel consistent with observations in
Financing Will Significantly Strengthen the Balance Sheet and Extend Cash Runway Initial Draw of $40 Million Will Retire $30 Million of the Principal Amount of
MONTREAL, July 12, 2022 (GLOBE NEWSWIRE) — CQDM, the Quebec Breast Cancer Foundation and Theratechnologies today announced close to CAN $2 million of funding for
MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative
MONTREAL, May 31, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and
